Novartis' Securing of Mariana Oncology: A $1 Billion Interest in Disease Development

In a milestone move inside the drug business, Novartis has disclosed its arrangements to procure Mariana Oncology for a faltering $1 billion. This essential understanding highlights Novartis' steadfast obligation to propelling oncology research and changing malignant growth treatment ideal models on a worldwide scale.